Skip to content

AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE II BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK1/2/3, ROS1, OR ALK GENE REARRANGEMENTS

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-505034-10-00
Acronym
GO40782
Enrollment
131
Registered
2024-06-27
Start date
2016-08-01
Completion date
Unknown
Last updated
2025-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Brief summary

Objective Response Rate (ORR), defined as the proportion of patients with complete response (CR) or partial response (PR)

Detailed description

Duration of Response (DOR), Time to Response (TTR), Clinical Benefit Rate (CBR), Intracranial tumor response in patients with measurable brain metastases, as determined by BICR using RANO or RANO-BM as applicable, CNS Progression-Free Survival (CNS-PFS) in patients with measurable CNS disease,, Progression-Free Survival (PFS), Overall Survival (OS), Type, incidence, severity, timing, seriousness, and relatedness of adverse events and laboratory abnormalities, Population PK, Ventricular repolarization, Quality-of-life and health status to examine biological markers of bone formation and resorption and markers of calcium metabolism, Assessment of bone mineral density (BMD) via dual X-ray absorptiometry (DXA) scans

Interventions

Sponsors

F. Hoffmann-La Roche AG
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Objective Response Rate (ORR), defined as the proportion of patients with complete response (CR) or partial response (PR)

Secondary

MeasureTime frame
Duration of Response (DOR), Time to Response (TTR), Clinical Benefit Rate (CBR), Intracranial tumor response in patients with measurable brain metastases, as determined by BICR using RANO or RANO-BM as applicable, CNS Progression-Free Survival (CNS-PFS) in patients with measurable CNS disease,, Progression-Free Survival (PFS), Overall Survival (OS), Type, incidence, severity, timing, seriousness, and relatedness of adverse events and laboratory abnormalities, Population PK, Ventricular repolarization, Quality-of-life and health status to examine biological markers of bone formation and resorption and markers of calcium metabolism, Assessment of bone mineral density (BMD) via dual X-ray absorptiometry (DXA) scans

Countries

France, Germany, Italy, Netherlands, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026